You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Completely Resected Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Plasma ctDNA
  • FFPE blocks
  • Angers, France
  • +35 more
Sep 19, 2023

NSCLC Trial in Seoul (concurrent chemoradiotherapy, chemo only)

Completed
  • Non-small Cell Lung Cancer
  • concurrent chemoradiotherapy
  • chemotherapy only
  • Seoul, Korea, Republic of
    Samsung Medical Center
Mar 18, 2021

NSCLC, Adjuvant Chemo Trial in Spain (Carboplatin, Paclitaxel, Nivolumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • Adjuvant Chemotherapy
  • Badalona, Barcelona, Spain
  • +29 more
Jun 1, 2022

Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Knoxville, Tennessee
    University of Tennessee Medical Center
Dec 20, 2022

NSCLC Trial in Shanghai

Not yet recruiting
  • Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Jul 20, 2023

    NSCLC Trial in Villejuif (other, procedure, radiation)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • clinical observation
    • +2 more
    • Villejuif, Val De Marne, France
      Institut Gustave Roussy
    Nov 18, 2020

    Identify Resected Non-small-cell Lung Cancer With High Risk of

    Recruiting
    • Non-small Cell Lung Cancer Stage IIIA
    • Resected non small cell lung cancer
    • Toulouse, France
      Julien MAZIERES
    Feb 8, 2023

    NSCLC Trial in France, Germany, United States (Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Adjuvant Chemotherapy
    • +2 more
    • Springdale, Arkansas
    • +50 more
    Jan 31, 2023

    NSCLC Trial (V940, Pembrolizumab, Placebo)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • V940
    • +2 more
    • (no location specified)
    Oct 5, 2023

    NSCLC Stage IIIA, Radiotherapy Trial in Shanghai (PORT, Platinum-based two drug chemo (cisplatin/carboplatin + vinorelbine or

    Unknown status
    • Non-small Cell Lung Cancer Stage IIIA
    • Radiotherapy
    • PORT
    • Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 12, 2020

    Resectable Lung Non-Small Cell Carcinoma Trial in Atlanta (procedure, radiation, other)

    Not yet recruiting
    • Resectable Lung Non-Small Cell Carcinoma
    • Biospecimen Collection
    • +2 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Aug 22, 2023

    Aggressive Histological Pattern in Resected Non-small Cell Lung

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • PET/CT-based Deep Learning Signature
    • Zunyi, Guizhou, China
    • +2 more
    Jun 27, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    NSCLC Stage IIIA, Radiotherapy Trial in Shanghai (PORT-first, PORT-last, Platinum-based two drug chemo (cisplatin/carboplatin +

    Unknown status
    • Non-small Cell Lung Cancer Stage IIIA
    • Radiotherapy
    • PORT-first
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 12, 2020

    NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Durvalumab + SoC chemotherapy
    • Placebo + SoC chemotherapy
    • Birmingham, Alabama
    • +147 more
    Aug 1, 2022

    IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung

    Completed
    • Non Small Cell Lung Cancer
    • Protein expression by immunohistochemistry and immunofluorescence
    • Rozzano, Milan, Italy
      Istituto Clinco Humanitas
    Sep 8, 2022

    NSCLC, Stage I Trial (Tislelizumab monotherapy)

    Not yet recruiting
    • NSCLC, Stage I
    • Tislelizumab monotherapy
    • (no location specified)
    Mar 9, 2022

    NSCLC Trial in Changchun (Almonertinib, Placebo Almonertinib)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Changchun, Jilin, China
      Jilin Province Cancer Hospital
    Jun 13, 2022

    DevelopingShared Decision Making Tool for Surgically Removed

    Recruiting
    • Lung Non-Small Cell Carcinoma
    • Discussion
    • Questionnaire Administration
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

    Not yet recruiting
    • Recurrent Bladder Carcinoma
    • +2 more
    • Pharmacokinetic Study
    • Recombinant EphB4-HSA Fusion Protein
    • Los Angeles, California
      USC / Norris Comprehensive Cancer Center
    Jan 31, 2023

    Nsclc Trial in Montpellier (Blood sample)

    Recruiting
    • Nsclc
    • Blood sample
    • Montpellier, France
      University Hospital
    Apr 27, 2022

    NSCLC Trial in Denmark, Norway (Will look for immune infiltration)

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • Will look for immune infiltration
    • København, København Ø, Denmark
    • +4 more
    Jan 6, 2022

    Lungcancer Trial in France (preoperative chest physiotherapy, preoperative rehabilitation program)

    Recruiting
    • Lungcancer
    • preoperative chest physiotherapy
    • preoperative rehabilitation program
    • Clermont-Ferrand, France
    • +5 more
    Mar 9, 2022

    Strategy for Resected NSCLC Longitudinal Undetectable MRD

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Molecular residual disease test
    • (no location specified)
    Jul 9, 2022

    Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be

    Completed
    • Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected
    • Talimogene Laherparepvec
    • Chicago, Illinois
    • +2 more
    Nov 17, 2022